lemzoparlimab (ABBV-IMAB-TJC4)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

I-Mab

Drug class:

CD47 inhibitor

Related drugs:

‹

›

CD47 overexpression + CD38 underexpression	Multiple Myeloma	CD47 overexpression + CD38 underexpression	Multiple Myeloma	ABBV-IMAB-TJC4 + MOR202 Sensitive: D – Preclinical ABBV-IMAB-TJC4 + MOR202 Sensitive : D	ABBV-IMAB-TJC4 + MOR202 Sensitive: D – Preclinical ABBV-IMAB-TJC4 + MOR202 Sensitive : D
HER-2 underexpression	Breast Cancer	HER-2 underexpression	Breast Cancer	disitamab vedotin + ABBV-IMAB-TJC4 Sensitive: D – Preclinical disitamab vedotin + ABBV-IMAB-TJC4 Sensitive : D	disitamab vedotin + ABBV-IMAB-TJC4 Sensitive: D – Preclinical disitamab vedotin + ABBV-IMAB-TJC4 Sensitive : D

Associations
(2)